摘要
肺癌患者的合并症是常见的临床问题。文章主要讨论肺癌患者合并慢性阻塞性肺疾病、肺栓塞、间质性肺疾病的临床状况及相关处理。总体来说,对于合并这3种呼吸系统疾病的肺癌患者,针对肺癌的治疗选择会受到限制,相较于无合并症者生存期更短、病死率更高。
Lung cancer comorbidity is common in patients. This review focuses on the clinical situations and treatment of patients with both lung cancer and one of the following: chronic obstructive pulmonary disease(COPD), pulmonary embolism(PE) or interstitial lung disease(ILD). Generally, these patients have more limitations on selecting cancer-related therapies, and they have shorter survival time and higher mortality than patients who had lung cancers only.
引文
[1]Nilsson J,Berglund A,Bergstr?m S,et al.The role of comorbidity in the management and prognosis in nonsmall cell lung cancer:a populationbased study[J].Acta Oncologica,2017,56(7):949-956.
[2]Wang C,Xu J,Yang L,et al.Prevalence and risk factors of chronic obstructive pulmonary disease in China(the China Pulmonary Health[CPH]study):a national cross-sectional study[J].Lancet(London England),2018,391(10131):1706-1717.
[3]Loganathan RS,Stover DE,Shi W,et al.Prevalence of COPD in women compared to men around the time of diagnosis of primary lung cancer[J].Chest,2006,129(5):1305-1312.
[4]Yi Ys,Ban Wh,Sohng Ky.Effect of COPD on symptoms,quality of life and prognosis in patients with advanced non-small cell lung cancer[J]BMC Cancer,2018,18(1):1053.
[5]Dy Sm,Sharkey P,Herbert R,et al.Comorbid illnesses and health care utilization among Medicare beneficiaries with lung cancer[J].Crit Rev Oncol Hematol,2006,59(3):218-225.
[6]Inoue T,Shiomi H,Oh Rj.Stereotactic body radiotherapy for Stage I lung cancer with chronic obstructive pulmonary disease:special reference to survival and radiation-induced pneumonitis[J].J Radiat Res,2015,56(4):727-734.
[7]Wang J,Cao J,Yuan S,et al.Poor baseline pulmonary function may not increase the risk of radiation-induced lung toxicity[J].Int J Radiat Oncol Biol Phys,2013,85(3):798-804.
[8]Takeda A,Kunieda E,Ohashi T,et al.Severe COPD Is Correlated With Mild Radiation Pneumonitis Following Stereotactic Body Radiotherapy[J].Chest,2012,141(4):858-866.
[9]Kiri VA,Soriano J,Visick G,et al.Recent trends in lung cancer and its association with COPD:an analysis using the UK GP Research Database[J].Prim Care Respir J,2010,19(1):57-61.
[10]Gao YH,Guan W J,Liu Q,et al.Impact of COPD and emphysema on survival of patients with lung cancer:A meta-analysis of observational studies[J].Respirology,2016,21(2):269-279.
[11]Grills I S,Mangona VS,Welsh R,et al.Outcomes after stereotactic lung radiotherapy or wedge resection for stage I non-small-cell lung cancer[J].J Clin Oncol,2010,28(6):928-935.
[12]Mokhles S,Verstegen N,Maat AP,et al.Comparison of clinical outcome of stage I non-small cell lung cancer treated surgically or with stereotactic radiotherapy:Results from propensity score analysis[J]Lung Cancer,2015,87(3):283-289.
[13]Eapen MS,Hansbro PM,Larsson-Callerfelt AK,et al.Chronic Obstructive Pulmonary Disease and Lung Cancer:Underlying Pathophysiology and New Therapeutic Modalities[J].Drugs,201878(16):1717-1740.
[14]Troosters T,Casaburi R,Gosselink R,et al.Pulmonary Rehabilitation in Chronic Obstructive Pulmonary Disease[J].Am J Respir Crit Care Med,2005,172(1):19-38.
[15]Cavalheri V,Granger C.Preoperative exercise training for patients with non-small cell lung cancer[M].Chichester,UK:John Wiley&Sons Ltd,1996.
[16]Cavalheri V,Tahirah F,Nonoyama M,et al.Exercise training for people following lung resection for non-small cell lung cancer-a Cochrane systematic review[J].Cancer Treat Rev,2014,40(4):585-594.
[17]Wiskemann J,Hummler S,Diepold C,et al.POSITIVE study:physical exercise program in non-operable lung cancer patients undergoing palliative treatment[J].BMC Cancer,2016,16(1):16:499.
[18]Edbrooke L,Aranda S,Granger CL,et al.Benefits of home-based multidisciplinary exercise and supportive care in inoperable non-small cell lung cancer-protocol for a phase II randomised controlled trial[J]BMC Cancer,2017,17(1):663.
[19]Sin DD,Wu L,Anderson JA,et al.Inhaled corticosteroids and mortality in chronic obstructive pulmonary disease[J].Thorax,200560(12):992-997.
[20]R ay makers A J,Mccormick N,Marra CA,et al.Do inhaled corticosteroids protect against lung cancer in patients with COPD?Asystematic review[J].Respirology,2017,22(1):61-70.
[21]S?rensen H T,Mellemkj?r L,Olsen JH,et al.Prognosis of Cancers Associated with Venous Thromboembolism[J].N Engl J Med,2000343(25):1846-1850.
[22]Li Y,Shang Y,Wang W,et al.Lung Cancer and Pulmonary Embolism:What Is the Relationship?A Review[J].J Cancer,2018,9(17):3046-3057.
[23]Ma L,Wen Z.Risk factors and prognosis of pulmonary embolism in patients with lung cancer[J].Medicine(Baltimore),2017,96(16):e6638.
[24]Christensen T D,Vad H,Pedersen S,et al.Venous thromboembolism in patients undergoing operations for lung cancer:a systematic review[J].Ann Thorac Surg,2014,97(2):394-400.
[25]Sun JM,Kim TS,Lee J,et al.Unsuspected pulmonary emboli in lung cancer patients:the impact on survival and the significance of anticoagulation therapy[J].Lung Cancer,2010,69(3):330-336.
[26]Konstantinides SV.2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism[J].Eur Heart J,201435(43):3033-3073.
[27]MahéI,Chidiac J,Bertoletti L,et al.The Clinical Course of Venous Thromboembolism May Differ According to Cancer Site[J].Am JMed,2017,130(3):337-347.
[28]Shinagare A B,Ok ajima Y,Ox nard GR,et al.Unsuspected pulmonary embolism in lung cancer patients:Comparison of clinical characteristics and outcome with suspected pulmonary embolism[J].Lung Cancer,2012,78(2):161-166.
[29]Zhang J,Zhang YL,Ma KX,et al.Efficacy and safety of adjunctive anticoagulation in patients with lung cancer without indication for anticoagulants:a systematic review and meta-analysis[J].Thorax2013,68(5):442-450.
[30]Zhang J,Zhang YL,Ma KX,et al.Efficacy and safety of adjunctive anticoagulation in patients with lung cancer without indication for anticoagulants:a systematic review and meta-analysis[J].Thorax2013,68(5):442-450.
[31]Fuentes HE,Oramas DM,Paz LH,et al.Meta-analysi s on anticoagulation and prevention of thrombosis and mortality among patients with lung cancer[J].Thromb Res,2017,154:28-34.
[32]Archontogeorgis K,Steiropoulos P,Tzouvelekis A,et al.Lung Cancer and Interstitial Lung Diseases:A Systematic Review[J].Pulm Med2012,2012(1):1-11.
[33]Raghu G,Nyberg F,Morgan G.The epidemiology of interstitial lung disease and its association with lung cancer[J].Br J Cancer,2004,91Suppl 2(S2):S3-10.
[34]Miyazaki K,Satoh H,Kurishima K,et al.Interstitial lung disease in patients with small cell lung cancer[J].Med Oncol,2010,27(3):763-767.
[35]Chen H,Senan S,Nossent EJ,et al.Treatment-Related Toxicity in Patients With Early-Stage Non-Small Cell Lung Cancer and Coexisting Interstitial Lung Disease:A Systematic Review[J].Int J Radiat Oncol Biol Phys,2017,98(3):622-631.
[36]Sato T,Teramukai S,Kondo H,et al.Impact and predictors of acute exacerbation of interstitial lung diseases after pulmonary resection for lung cancer[J].J Thorac Cardiovasc Surg,2014,147(5):1604-1611.
[37]Kato T,Masuda N,Nakanishi Y,et al.Nivolumab-induced interstitial lung disease analysis of two phase II studies patients with recurrent or advanced non-small-cell lung cancer[J].Lung Cancer,2017,104:111-118.
[38]Tomassetti S,Gurioli C,Ryu JH,et al.The Impact of Lung Cancer on Survival of Idiopathic Pulmonary Fibrosis[J].Chest,2015,147(1):157-164.
[39]Mohamed S,Bayoumi H,El-Aziz NA,et al.Prevalence,risk factors,and impact of lung Cancer on outcomes of idiopathic pulmonary fibrosis:a study from the Middle East[J].Multidiscip Respir Med,2018,13:3.